Adial Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
Adial Pharmaceuticals, Inc. (ADIL) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$2.72 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2025-03-04
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2024-09-30 was -$0.38.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2024-06-30 was -$0.59.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2023-09-30 was -$1.14.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2023-06-30 was -$1.33.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2024 was -$2.72.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$4.91.
- Adial Pharmaceuticals, Inc. income (loss) from continuing operations, per diluted share for fiscal 2022 was -$10.78.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.72 10-K · filed 2025-03-04 | |||
| 2024-09-30 | -$0.38 10-Q · filed 2024-11-13 | -$2.57 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | -$0.59 10-Q · filed 2024-08-13 | -$2.50 10-Q · filed 2024-08-13 | ||
| 2023-12-31 | -$4.91 10-K · filed 2025-03-04 | |||
| 2023-09-30 | -$1.14 10-Q · filed 2024-11-13 | -$4.54 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$1.33 10-Q · filed 2024-08-13 | -$3.42 10-Q · filed 2024-08-13 | ||
| 2022-12-31 | -$10.78 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$2.48 10-Q · filed 2023-11-14 | -$8.31 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$3.33 10-Q/A · filed 2023-10-30 | -$6.10 10-Q/A · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |